|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies显示文摘 | Keystone E Emery P Peterfy C G | 2009 | Ann Rheum Dis2009，68，： | 1 |
| 2 | Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients显示文摘 | Ronald F van Vollenhoven Paul Emery Clifton O Bingham Edward C Keystone Roy M Fleischmann Daniel E Furst Nicola Tyson Neil Collinson Patricia B Lehane | 2013 | Annals of the Rheumatic Diseases2013，，9： | 1 |
| 3 | Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010显示文摘 | Furst DE Keystone E C Braun J etal | 2011 | Ann Rheum Dis2011，70，1： | 1 |
| 4 | Updated Consen- sus Statement on Biological Agents for the Treatment of Rheumatic Diseases,2011显示文摘 | Furst D E Keystone E C Braun J | 2012 | Ann Rheum Dis2012，71，12： | 1 |
| 5 | Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis:ARMADA 4 year extended study显示文摘 | Keystone E C Furst D E | 2006 | Annals of the Rheumatic Diseases2006，65，： | 1 |
| 6 | Alefacept in comhi- nation with methotrexate for the treatment of psoriatic arthri- tis: Results of a randomized, double-blind, placebn-controlled sludy显示文摘 | Mease P J Gladman D D Keystone E C | 2006 | Arthritis Rheum2006，54，： | 1 |
| 7 | Golimumab,a human antibody to TNF-α given by monthly subcutaneous injections,in active rheumatoid arthritis desp-ite methotrexate:The GO-FORWARD Study显示文摘 | Keystone E C Genovese M C Klareskog L | 2008 | Ann Rheum Dis2008，136，： | 1 |
| 8 | The safety of anti-tumor necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events 显示文摘 | LEOMBRUNO J P EINARSON T R KEYSTONE E C | 2009 | Ann Rheum Dis2009，68，7： | 1 |
| 9 | Radiographic, clini- cal, and functional outcomes of treatment with adalimumab( a human an- ti - tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a ran- domized, placebo - controlled, 52 - week trial 显示文摘 | Keystone E C Kavanaugh A F Sharp J T | 2004 | Arthritis Rheum2004，50，： | 1 |
| 10 | The safety of anti tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events 显示文摘 | Leombruno J P Einarson T R Keystone E C | 2009 | Ann Rheum Dis2009，68，7： | 1 |
| 11 | Updated con-sensus statement on biological agents for the treatment ofrheumatic diseases,2011 显示文摘 | FURST D E KEYSTONE E C BRAUN J | 2012 | Ann Rheum Dis2012，71，2： | 1 |
| 12 | Updated consensus statement on biological agents for the treatment of rheumatic diseases 显示文摘 | Furst D E Keystone E C Fleischmann R | 2010 | Ann Rheum Dis2010，69，： | 1 |
| 13 | Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012显示文摘 | Furst D E Keystone E C So A K | 2013 | Ann Rheum Dis2013，72，2： | 1 |
| 14 | The utility of tumour necrosis factor blockade in orphan disease 显示文摘 | Keystone E C | 2004 | Ann Rheum Dis2004，63，： | 1 |
| 15 | The utility of turnout necrosis factor blockade in orphan disease显示文摘 | Keystone E C | 2004 | Ann Rheum Dis2004，63，： | 1 |
| 16 | Anti-tumor necrosis factor agents and tuberculosis risk:mechanisms of action and clinical management显示文摘 | GARDAM M A KEYSTONE E C MENZIES R | 2003 | Lancet Infect Dis2003，3，3： | 1 |
| 17 | Baricitinib, an oral janus kinase inhibitor, in the treatment of rheumatoid arthritis: 52-week safety and efficacy in an open-label, long-term extension study显示文摘 | Taylor P Genovese M C Keystone E | 2013 | Ann Rheum Dis2013，72，3： | 1 |
| 18 | Tumor necrosis factor2alpha blockade in the treatment of rheumatoid arthritis 显示文摘 | Keystone E C | 2001 | Rheum Dis Clin North Am2001，27，： | 1 |
| 19 | Adalimumab response in patients with early versus established rheumatoid arthritis:DEO19 randomized controlled trial subanalysis显示文摘 | Jamal S Patra K Keystone E C | 2009 | Clin Rheumatol2009，28，4： | 1 |
| 20 | Updated consensus statement on biologicalagents for the treatment of rheumatic diseases, 2008显示文摘 | Furst D E Keystone E C Kirkham B | 2008 | Ann Rheum Dis2008，67，3： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员